GSK exec foresees more M&A in the industry

11/9/2010 | Reuters

David Redfern, chief strategy officer at GlaxoSmithKline, said mergers and acquisitions in the drug industry likely will continue and that investors might see more major deals as companies attempt to avoid market pressure. However, GlaxoSmithKline will stick to smaller purchases because the company does not rely on deals to fill holes in its drug portfolio, Redfern said. "As the major Western markets slow down, M&A has been seen as a way of getting more top-line growth," he said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI